News

This systematic review highlights current research on ruxolitinib’s off-label use in dermatology, specifically for conditions such as alopecia and psoriasis.

Ultrasound showed no significant dermis thickness difference at the cubital fossa, yet dust mite-sensitized kids had signs of allergen-driven skin changes.

Valerie Louis outlined her ASKmeGOC study and the electronic tool her team developed to help preemptively record preferences.

Tumlin reviews findings from a posthoc analysis of DUPLEX demonstrating sparsentan’s impact on partial remission, complete remission, and kidney failure.

Zehavi Horowitz-Kugler, MD, and Ran Shaul discussed an AI model K Health developed and evaluated in a virtual urgent care clinic.

Bristol Myers Squibb says mavacamten missed dual primary endpoints in Phase 3 ODYSSEY-HCM trial for symptomatic non-obstructive HCM.

These data on 5α-reductase inhibitors highlight impacts on patients with benign prostatic hyperplasia or androgenic alopecia.

Adrienne Poon, MD, MPH, discussed early findings from a community health needs survey of AAPI populations.

In children with septic shock, norepinephrine as the first vasoactive agent was linked to lower 30-day mortality than epinephrine, with no renal outcome difference.

Bhatt discusses his expectations for the future of cardiology in 2025, including GLP-1-RAs and the push towards combination therapy.

A single infusion of VERVE-102 gene editing therapy achieved dose-dependent lowering in blood PCSK9 and LDL-C in initial results from the Heart-2 trial.

This segment of the latest interview with Lawrence Eichenfield, MD, features a discussion about the ICONIC-LEAD study.

The new tablet formulation of maralixibat for the treatment of cholestatic pruritus in patients with ALGS and PFIC is expected to be available in June.

In this Q&A, Augsten discusses treatment strategies, challenges, and non-pharmacological interventions for schizophrenia and bipolar I disorder based on recent survey findings.

Lafayette reflects on recent therapeutic advances in IgA nephropathy and looks ahead to other renal pipeline developments he’s looking forward to in 2025.

Anemia correction reduced perioperative rates but showed no significant impact on postoperative outcomes, emphasizing the need for prehabilitation strategies.

Erickson encouraged clinicians to get involved in advocacy for health policy issues they are passionate about.

An audio recap of the top 5 stories in healthcare news from the week of 03/31-04/06.

In this interview, Lawrence Eichenfield, MD, speaks on his team’s recent research on icotrokinra for patients with moderate-to-severe plaque psoriasis.

HCPLive spoke with Kane about new phase 2 data showing that an oral benzamide provides a significant change from baseline in CGI-S scores for participants with acute schizophrenia.

Phase 4 trial results showed switching to BSV after long-term TDF was noninferior for antiviral efficacy and led to improved kidney function and bone density.

Our top 5 headlines spotlight developments in AI-driven care, diabetes tech, and dermatology, alongside key FDA actions in ophthalmology and nephrology.

Herzig discussed special considerations for treating pain in people with OUD.

Acute respiratory infection caused by RSV results in a nearly 3-fold increase in mortality, particularly in those with underlying respiratory conditions.

Gelles discussed potential concerns with AI’s use in reducing administrative burden but stressed its promise.

Payal Kohli, MD, explores how evolving tools and strategies in lipid management are reshaping preventive cardiology.

Erickson discussed how federal travel restrictions put critical patient care and workforce stability at risk.

This analysis demonstrates the effectiveness of methotrexate application via microinfusion in frontal fibrosing alopecia.